Kiniksa Pharmaceuticals International (KNSA) to Release Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $200.8550 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International Trading Up 1.3%

KNSA opened at $47.77 on Friday. The business has a 50 day moving average of $42.72 and a 200-day moving average of $39.41. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of 106.16 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 1-year low of $18.25 and a 1-year high of $47.86.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 2,690 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at $564,570. This trade represents a 17.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 123,823 shares of company stock valued at $5,244,967. Corporate insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently modified their holdings of KNSA. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at about $31,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $36,000. CIBC Private Wealth Group LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. Finally, Quantbot Technologies LP bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $43,000. 53.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research note on Thursday. They set a “buy” rating and a $62.00 price objective for the company. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.71.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.